Abdom Radiol (NY)

1. KONG L, Ling J, Cao W, Wen Z, et al
   Multiparametric MR characterization for human epithelial growth factor receptor 2 expression in bladder cancer: an exploratory study.
   Abdom Radiol (NY). 2024 Jun 13. doi: 10.1007/s00261-024-04378.
   

   >> Share

   
   

   
   ACS Nano

2. LI Q, Zhan S, Yang X, Zhang Z, et al
   Choline Phosphate-Grafted Nanozymes as Universal Extracellular Vesicle Probes for Bladder Cancer Detection.
   ACS Nano. 2024 Jun 10. doi: 10.1021/acsnano.4c00280.
   

   >> Share

   
   

   
   Altern Ther Health Med

3. FENG K
   Effectiveness of Comprehensive Nursing Intervention Based on the Roy Adaptation Model in the Perioperative Period of Bladder Cancer.
   Altern Ther Health Med. 2024 Jun 14:AT10139.
   

   >> Share

   
   

   
   Am J Cancer Res

4. JIANG J, Xu J, Ou L, Yin C, et al
   ITM2A inhibits the progression of bladder cancer by downregulating the phosphorylation of STAT3.
   Am J Cancer Res. 2024;14:2202-2215.
   

   >> Share

   
   

   
   Am Soc Clin Oncol Educ Book

5. VLACHOU E, Johnson BA 3rd, Baraban E, Nadal R, et al
   Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer.
   Am Soc Clin Oncol Educ Book. 2024;44:e438640.
   

   >> Share

   
   

   
   Ann Surg Oncol

6. SONG W, Yu J, Chung JH, Kang M, et al
   A Proposal for Standardization of Early Outcomes Following Robot-Assisted Radical Cystectomy (RARC): RARC Tetrafecta.
   Ann Surg Oncol. 2024;31:4752-4761.
   

   >> Share

   
   

   
   Arch Gynecol Obstet

7. SCHRODER C, Ploger R, Knupfer S, Tascon Padron L, et al
   Anterior enterocele after cystectomy: case report and review of the literature.
   Arch Gynecol Obstet. 2024;310:11-21.
   

   >> Share

   
   

   
   Biochem Genet

8. CHI Q, Wang Z, Xu H, Li H, et al
   Circ_0000758 Facilitates Bladder Cancer Cell Growth, Migration and Angiogenesis Via Severing as miR-1236-3p Sponge.
   Biochem Genet. 2024 Jun 13. doi: 10.1007/s10528-024-10855.
   

   >> Share

   
   
9. ZHANG P, Song D, Fang Z, Sun D, et al
   Cardamomin Inhibits the Proliferation and Tumorigenesis of Bladder Cancer by ESR1 in PI3K/AKT Pathway.
   Biochem Genet. 2024 Jun 12. doi: 10.1007/s10528-024-10854.
   

   >> Share

   
   

   
   BJUI Compass

10. LAHOUD J, Patel MI, Naher S, Mercieca-Bebber R, et al
    A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion.
    BJUI Compass. 2024;5:524-540.
    

    >> Share

    
    

    
    BMC Cancer

11. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    

    >> Share

    
    

    
    BMC Ophthalmol

12. WANG JN, Zhang Y, Huang CY, Li K, et al
    Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    BMC Ophthalmol. 2024;24:240.
    

    >> Share

    
    

    
    BMC Urol

13. ZAREINEJAD M, Faghih Z, Ramezani A, Safaei A, et al
    Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6.
    BMC Urol. 2024;24:124.
    

    >> Share

    
    

    
    BMJ Open

14. REZAEE ME, Mahon KM, Trock BJ, Nguyen TE, et al
    ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.
    BMJ Open. 2024;14:e076763.
    

    >> Share

    
    

    
    Cancer Biol Ther

15. HUANG J, Michaud E, Shinde-Jadhav S, Fehric S, et al
    Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model.
    Cancer Biol Ther. 2024;25:2365452.
    

    >> Share

    
    

    
    Clin Transl Oncol

16. COELHO JQ, Ramos MJ, Ranchor R, Pichel R, et al
    What's new about the tumor microenvironment of urothelial carcinoma?
    Clin Transl Oncol. 2024;26:1549-1560.
    

    >> Share

    
    

    
    Diagn Pathol

17. FAHOUM I, Tsuriel S, Rattner D, Greenberg A, et al
    Automatic analysis of nuclear features reveals a non-tumoral predictor of tumor grade in bladder cancer.
    Diagn Pathol. 2024;19:75.
    

    >> Share

    
    

    
    Eur J Med Res

18. DU L, Wang B, Wen J, Zhang N, et al
    No causal association between insomnia and bladder cancer: a bidirectional two-sample Mendelian randomization study.
    Eur J Med Res. 2024;29:316.
    

    >> Share

    
    

    
    Eur Urol Focus

19. MCINERNEY S, Jones RJ
    Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
    Eur Urol Focus. 2024 Jun 7:S2405-4569(24)00075-0. doi: 10.1016/j.euf.2024.
    

    >> Share

    
    
20. DAY E, Gavira J, Tapia JC, Anguera G, et al
    What About Variant Histologies in Bladder Cancer?
    Eur Urol Focus. 2024 Jun 6:S2405-4569(24)00078-6. doi: 10.1016/j.euf.2024.
    

    >> Share

    
    

    
    Eur Urol Oncol

21. GUERRERO-RAMOS F, Boormans JL, Daneshmand S, Gontero P, et al
    Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2024 Jun 6:S2588-9311(24)00143-3. doi: 10.1016/j.euo.2024.
    

    >> Share

    
    

    
    Expert Opin Biol Ther

22. KHENE ZE, Lotan Y
    An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
    Expert Opin Biol Ther. 2024 Jun 13:1-9. doi: 10.1080/14712598.2024.2365802.
    

    >> Share

    
    

    
    Front Artif Intell

23. BORNA MR, Sepehri MM, Shadpour P, Khaleghi Mehr F, et al
    Enhancing bladder cancer diagnosis through transitional cell carcinoma polyp detection and segmentation: an artificial intelligence powered deep learning solution.
    Front Artif Intell. 2024;7:1406806.
    

    >> Share

    
    

    
    Front Oncol

24. POON DMC, Ho LY, Kwong YM
    Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases.
    Front Oncol. 2024;14:1397738.
    

    >> Share

    
    
25. UYSAL D, Thaqi B, Fierek A, Jurgowski D, et al
    Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.
    Front Oncol. 2024;14:1370303.
    

    >> Share

    
    

    
    Front Pharmacol

26. PENG X, Liu C, Zhang L, Chen Y, et al
    IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Front Pharmacol. 2024;15:1365683.
    

    >> Share

    
    

    
    Future Oncol

27. YOO C, Lamarca A, Choi HJ, Vogel A, et al
    Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
    Future Oncol. 2024;20:1069-1077.
    

    >> Share

    
    

    
    Gene

28. ZHOU R, Zhou J, Deng S, Zhu Y, et al
    Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.
    Gene. 2024;927:148634.
    

    >> Share

    
    

    
    Heliyon

29. YANG Z, Li X, Zhou L, Luo Y, et al
    Ferroptosis-related lncRNAs: Distinguishing heterogeneity of the tumour microenvironment and predicting immunotherapy response in bladder cancer.
    Heliyon. 2024;10:e32018.
    

    >> Share

    
    

    
    Hum Pathol

30. ZHENG L, Chen H, Zhao J, Roy-Chowdhuri S, et al
    Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
    Hum Pathol. 2024;148:1-6.
    

    >> Share

    
    

    
    Insights Imaging

31. FAN Z, Guo J, Zhang X, Chen Z, et al
    Non-Gaussian diffusion metrics with whole-tumor histogram analysis for bladder cancer diagnosis: muscle invasion and histological grade.
    Insights Imaging. 2024;15:138.
    

    >> Share

    
    

    
    Int J Biol Markers

32. WANG X, Zhang S, Sun Y, Cai L, et al
    The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer.
    Int J Biol Markers. 2024 Jun 11:3936155241261719. doi: 10.1177/03936155241261719
    

    >> Share

    
    

    
    Int J Surg

33. ZHU X, He J, Chen J
    A commentary on "Genetically proxied intestinal microbiota and risk of bladder cancer".
    Int J Surg. 2024 Jun 10. doi: 10.1097/JS9.0000000000001780.
    

    >> Share

    
    

    
    Iran Biomed J

34. ALBADAWY A, Alqudaimi M, Cui H, Yan X, et al
    Identification of Hydroxysteroid Dehydrogenase Type 1 As a Potential Bladder Tumor Marker.
    Iran Biomed J. 2024;28.
    

    >> Share

    
    

    
    J Asian Nat Prod Res

35. ZHAI Z, Fu J, Ye ML, Wang JY, et al
    The changes of intestinal microbiota and metabolomics during the inhibition of bladder cancer by liquiritigenin.
    J Asian Nat Prod Res. 2024 Jun 13:1-10. doi: 10.1080/10286020.2024.2366010.
    

    >> Share

    
    

    
    J Magn Reson Imaging

36. LI J
    Editorial for "Amide Proton Transfer-Weighted Imaging in Assessing the Aggressive and Proliferative Potential of Bladder Cancer".
    J Magn Reson Imaging. 2024 Jun 13. doi: 10.1002/jmri.29468.
    

    >> Share

    
    

    
    J Oncol Pharm Pract

37. KHOSLA H, Bhatt S, Wang MJ, Gignac G, et al
    Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    J Oncol Pharm Pract. 2024;30:941-944.
    

    >> Share

    
    

    
    J Pathol

38. VANGURI RS, Smithy JW, Li Y, Zhuang M, et al
    Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
    J Pathol. 2023;261:349-360.
    

    >> Share

    
    

    
    J Urol

39. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Apr 22:101097JU0000000000003900. doi: 10.1097/JU.0000000000003900.
    

    >> Share

    
    
40. PATEL SH, Gabrielson AT, Chan S, Schwartz D, et al
    A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
    J Urol. 2024;212:95-103.
    

    >> Share

    
    
41. LOTAN Y, Daneshmand S, Shore N, Black P, et al
    A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
    J Urol. 2024;212:41-51.
    

    >> Share

    
    
42. LAZAROVICH A, Dahmen AS, Modi PK, Agarawal PK, et al
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024;212:236-237.
    

    >> Share

    
    
43. KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
    The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2024 Jun 7:101097JU0000000000004070. doi: 10.1097/JU.0000000000004070.
    

    >> Share

    
    

    
    JCO Precis Oncol

44. SATYAL U, Valentine H, Liu D, Slifker M, et al
    Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
    JCO Precis Oncol. 2024;8:e2300362.
    

    >> Share

    
    

    
    Mol Oncol

45. KAWAHARA I, Yoshino H, Fukumoto W, Arima J, et al
    Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
    Mol Oncol. 2024 Jun 14. doi: 10.1002/1878-0261.13684.
    

    >> Share

    
    
46. LAMMERT FC, Pannhausen J, Noetzel E, Friedland F, et al
    Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes.
    Mol Oncol. 2024;18:1397-1416.
    

    >> Share

    
    

    
    Rev Med Liege

47. DUCHENE L, Davenne E, Lifrange F, Detrembleur N, et al
    [Urinary cytology for the detection of urothelial lesions].
    Rev Med Liege. 2024;79.
    

    >> Share

    
    

    
    Sci Rep

48. LUO J, Luo F, Li Q, Liu Q, et al
    An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer.
    Sci Rep. 2024;14:13106.
    

    >> Share

    
    

    
    Toxicol In Vitro

49. ZHANG G, Wei W, Li S, Yang J, et al
    Transcription Factor yin-Yang 1 augments nucleoporin 93 oncogene activity and modulates bladder Cancer malignancy.
    Toxicol In Vitro. 2024 Jun 8:105875. doi: 10.1016/j.tiv.2024.105875.
    

    >> Share

    
    

    
    Transl Androl Urol

50. FANG K, Fang DL, Yu H, Chen YA, et al
    Exploring the microRNA-mRNA regulatory network associated with solasonine in bladder cancer.
    Transl Androl Urol. 2024;13:812-827.
    

    >> Share

    
    

    
    Urologia

51. PAKMANESH H, Khajehsalimi A, Hesamarefi M, Ebadzadeh MR, et al
    Comparison of the overall survival of different treatment methods in patients with Muscle-invasive bladder cancer: A retrospective study.
    Urologia. 2024 Jun 12:3915603241256009. doi: 10.1177/03915603241256009.
    

    >> Share

    
    

    
    Urology

52. YU J, Wang CG, Zhang Y, Yang W, et al
    A Novel Approach to Treatment with Antiangiogenic Agents in Adenocarcinoma of Urachal Origin.
    Urology. 2024;187:121-122.
    

    >> Share

    
    
53. BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
    Reply to Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
    Urology. 2024;187:139.
    

    >> Share

    
    
54. BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
    Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature.
    Urology. 2024;187:131-136.
    

    >> Share

    
    
55. LIN JS, Zhao LC
    Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
    Urology. 2024;187:137-138.
    

    >> Share

    
    
56. MORAN M, Kim JE, Fu MZ, Ghodoussipour S, et al
    Worsening Neobladder Incontinence in a Patient on Nivolumab Therapy.
    Urology. 2024;187:92-93.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share